
T2 Biosystems TTOO
Quartalsbericht 2024-Q3
hinzugefügt 16.05.2026
T2 Biosystems Langfristige Verbindlichkeiten 2011-2026 | TTOO
Langfristige Verbindlichkeiten Jährlich T2 Biosystems
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 60.6 M | 1.92 M | 625 K | 1.74 M | 40.3 M | 27.7 M | 21 M | 117 M | 72 M | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 117 M | 625 K | 38.1 M |
Langfristige Verbindlichkeiten anderer Aktien in der Diagnostik & Forschung
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
4.6 M | - | -8.98 % | $ 14.8 K | ||
|
Centogene N.V.
CNTG
|
23.7 M | - | -6.23 % | $ 30.6 M | ||
|
Heska Corporation
HSKA
|
57.9 M | - | - | $ 1.31 B | ||
|
Celcuity
CELC
|
69.2 K | $ 89.49 | -3.22 % | $ 4.18 B | ||
|
Akumin
AKU
|
527 M | - | -17.87 % | $ 25.9 M | ||
|
Co-Diagnostics
CODX
|
574 K | $ 5.6 | -2.76 % | $ 7.45 M | ||
|
Castle Biosciences
CSTL
|
2.76 M | $ 21.78 | 0.83 % | $ 631 M | ||
|
Aspira Women's Health
AWH
|
3.49 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
134 M | - | -61.36 % | $ 2.46 M | ||
|
Fulgent Genetics
FLGT
|
2.26 M | $ 19.49 | -0.08 % | $ 600 M | ||
|
Guardant Health
GH
|
91.4 M | $ 129.26 | -2.86 % | $ 16.2 B | ||
|
Biocept
BIOC
|
11.3 M | - | -13.05 % | $ 7.29 M | ||
|
ICON Public Limited Company
ICLR
|
461 M | $ 149.59 | -2.1 % | $ 11.7 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
7.74 M | - | - | $ 562 M | ||
|
CareDx, Inc
CDNA
|
17.9 M | $ 23.03 | -0.4 % | $ 1.23 B | ||
|
Illumina
ILMN
|
2.04 B | $ 163.18 | -2.9 % | $ 25.3 B | ||
|
Chembio Diagnostics
CEMI
|
24.8 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
16 K | - | - | $ 9.42 M | ||
|
Interpace Biosciences
IDXG
|
10 M | $ 1.79 | 2.29 % | $ 7.92 M | ||
|
HTG Molecular Diagnostics
HTGM
|
4.1 M | - | -20.0 % | $ 1.06 M | ||
|
Global Cord Blood Corporation
CO
|
2.53 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
131 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
161 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
48.5 M | - | 0.12 % | $ 80.1 M | ||
|
Mettler-Toledo International
MTD
|
1.61 B | $ 1 167.59 | -1.09 % | $ 24.1 B | ||
|
DermTech
DMTK
|
865 K | - | -11.32 % | $ 2.94 M | ||
|
Lantheus Holdings
LNTH
|
225 M | $ 103.0 | 0.17 % | $ 6.95 B | ||
|
NeoGenomics
NEO
|
435 M | $ 11.14 | -1.5 % | $ 1.43 B | ||
|
Charles River Laboratories International
CRL
|
2.35 B | $ 183.53 | -1.23 % | $ 9.1 B | ||
|
Natera
NTRA
|
124 M | $ 218.16 | -1.78 % | $ 29.8 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.43 B | - | - | $ 10.7 B | ||
|
Medpace Holdings
MEDP
|
73.8 M | $ 455.07 | -0.79 % | $ 13.1 B | ||
|
Exact Sciences Corporation
EXAS
|
981 M | - | - | $ 19.8 B | ||
|
National Research Corporation
NRC
|
39.6 M | $ 19.63 | -0.61 % | $ 439 M | ||
|
Myriad Genetics
MYGN
|
107 M | $ 4.61 | -1.71 % | $ 427 M | ||
|
Personalis
PSNL
|
639 K | $ 11.4 | -5.79 % | $ 1.02 B | ||
|
Koninklijke Philips N.V.
PHG
|
8.45 B | $ 26.34 | 1.33 % | $ 25 B | ||
|
Senseonics Holdings
SENS
|
163 M | $ 7.03 | 0.21 % | $ 293 M | ||
|
QIAGEN N.V.
QGEN
|
1.99 B | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
10.8 M | - | - | $ 2.69 B | ||
|
Biomerica
BMRA
|
1.57 M | $ 2.15 | - | $ 4.94 M | ||
|
Laboratory Corporation of America Holdings
LH
|
7.82 B | $ 263.55 | 0.93 % | $ 21.9 B | ||
|
Twist Bioscience Corporation
TWST
|
4.56 M | $ 69.6 | -5.86 % | $ 4.16 B | ||
|
Thermo Fisher Scientific
TMO
|
22.5 B | $ 475.78 | -1.31 % | $ 179 B | ||
|
Trinity Biotech plc
TRIB
|
106 M | $ 0.68 | -1.21 % | $ 244 M | ||
|
Motus GI Holdings
MOTS
|
2.16 M | - | -34.28 % | $ 263 K | ||
|
Neogen Corporation
NEOG
|
19.6 M | $ 9.03 | -1.04 % | $ 1.96 B | ||
|
Quest Diagnostics Incorporated
DGX
|
5.17 B | $ 199.38 | 1.64 % | $ 22.1 B | ||
|
Invitae Corporation
NVTA
|
320 M | - | - | $ 21.2 M | ||
|
Waters Corporation
WAT
|
1.28 B | $ 370.79 | -1.5 % | $ 22.1 B |